KLIPP - a precision CRISPR approach to target structural variant junctions in cancer
Yang, H.; Hulbatte, R. S.; Kellher, A.; Gratsch, N.; Wang, Y.; Palmbos, P.; Ljungman, M.
Show abstract
Current cancer therapies typically give rise to dose-limiting normal tissue toxicity. We have developed KLIPP, a precision cancer approach that specifically kills cancer cells using CRISPR/Cas9 technology. The approach consists of guide RNAs that target cancer-specific structural variant junctions to nucleate two parts of a dCas9-conjugated endonuclease, Fok1, leading to its activation. We show that KLIPP causes induction of DNA double strand breaks (DSBs) at the targeted junctions and cell death. When cancer cells were grown orthotopically in mice, activation of Fok1 at only two junctions led to the disappearance of tumor cells in 7/11 mice. This therapeutic approach has high specificity for tumor cells and is independent of tumor-specific drivers. Individualized translation of KLIPP to patients would be transformative and lead to consistent and simplified cancer treatment decisions.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing 95%
- The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling 95%
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 95%
Similar papers in this journal
- Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells 96%
- Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage 96%
- Ki-67 promotes sequential stages of tumourigenesis by enabling cellular plasticity 95%
Similar papers in this journal
- The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities. 94%
- CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers 94%
- Differential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesis in vivo 94%
Similar papers in this journal
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 94%
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 93%
- BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade 93%
Similar papers in this journal
- Co-regulation and functional cooperativity of FOXM1 and RHNO1 bidirectional genes in ovarian cancer 95%
- Exosome component 1 cleaves single-stranded DNA and sensitizes kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor 94%
- The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.